Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

This study has been terminated.
(Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.)
Sponsor:
Information provided by:
Neurogen Corporation
ClinicalTrials.gov Identifier:
NCT00834327
First received: January 30, 2009
Last updated: October 12, 2009
Last verified: October 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2009
  Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)